anesthesia glp-1 Are Serious Risks of Semaglutide and Other Agonists Under-Recognized? Case Reports of Retained Solid Gastric Contents in Patients Undergoing Anesthesia 🔸 Should GLP-1 RAs be

Nausea affects up to 20% of semaglutide users (Alhazmi 2026)

Explore BPS Biosciences solutions for GLP-1R research in diabetes

Medical eligibility depends on BMI, metabolic health, and individual risk factors evaluated by a qualified provider.

Only one in five patients on blockbuster weight loss drugs keep the pounds off after stopping the medication, and almost 20 percent regained the weight, a study from Epic Research found.

Irisin, a myokine released during physical exercise, has emerged as a key mediator of muscle health and metabolic regulation

Een nieuwe studie, die onlangs is gepubliceerd in JAMA Network Open, suggereert dat GLP-1 (glucagon-like peptide-1) receptoragonisten, die momenteel goedgekeurd zijn voor de behandeling van diabetes en obesitas, mogelijk een bijkomend voordeel hebben: ze kunnen het risico op bepaalde met obesitas geassocieerde kankers (obesity associated cancers, OACs) verminderen